Cholangiocarcinoma and gallbladder cancer

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Cholangiocarcinoma arises from intrahepatic or extrahepatic biliary epithelium, while gallbladder carcinoma may be discovered symptomatically or incidentally after cholecystectomy; anatomy governs drainage, biopsy strategy and surgical planning. Primary sclerosing cholangitis, choledochal cysts, hepatolithiasis and liver-fluke infection increase cholangiocarcinoma risk through repeated epithelial injury. Long-standing gallstones, porcelain gallbladder and large polyps are associated with chronic inflammation and selected gallbladder cancers. Perihilar and distal tumours narrow bile ducts, producing upstream cholestasis, pruritus, infection and impaired hepatic function. Biliary cancers spread longitudinally along ducts, through perineural planes and into portal structures, making margin assessment and resectability complex.

Recognition depends on the tempo, host context and anatomical pattern rather than one isolated result. Extrahepatic obstruction causes jaundice, pruritus, dark urine and pale stool, often before a mass is palpable. Fever, rigors, pain, confusion or shock with obstruction requires emergency antibiotics and drainage. Pain, weight loss or an incidental liver mass may occur without jaundice until disease is advanced. Investigation should answer immediate safety, diagnostic confirmation and extent in that order. Contrast CT chest, abdomen and pelvis Use before unplanned drainage or biopsy where stable; perihilar disease needs expert review of future liver remnant and ductal anatomy. MRI with MRCP This is especially valuable for perihilar tumours and avoids losing key anatomical information after stent artefact or decompression. Endoscopic or percutaneous tissue Brushings alone have limited sensitivity; combine cytology, biopsy and molecular methods as appropriate, and avoid transperitoneal hilar-mass biopsy if transplant could be considered.

Management is determined by physiological urgency, disease extent, treatment intent and the person's priorities. The pathway moves through define anatomy before intervention, then control infected or clinically important obstruction, then pursue curative surgery in a specialist centre; each transition requires named multidisciplinary ownership. Follow-up must anticipate recurrent cholangitis, liver failure, stent occlusion while measuring function and treatment toxicity.

Key points

Painless cholestatic jaundice is a pivotal clue in Cholangiocarcinoma and gallbladder cancer: Extrahepatic obstruction causes jaundice, pruritus, dark urine and pale stool, often before a mass is palpable.
Immediate priority in unstable Cholangiocarcinoma and gallbladder cancer: Use sepsis care, take cultures, give intravenous antibiotics and arrange urgent endoscopic or percutaneous biliary drainage with hepatobiliary expertise, selecting ducts deliberately in perihilar obstruction.
Contrast CT chest, abdomen and pelvis is used early to define primary anatomy, vascular involvement, nodes, metastases and broad resectability. Use before unplanned drainage or biopsy where stable; perihilar disease needs expert review of future liver remnant and ductal anatomy.
MRI with MRCP refines the next decision because this is especially valuable for perihilar tumours and avoids losing key anatomical information after stent artefact or decompression.
Define anatomy before intervention: Obtain contrast CT and MRI/MRCP before stenting when feasible, then review ducts, vessels, lobar atrophy, future remnant and metastases in the hepatobiliary MDT.
Control infected or clinically important obstruction: Drain the infected and intended functional liver segments rather than maximising the number of stents without a map.
A major avoidable harm is recurrent cholangitis; Incomplete or occluded drainage allows infected bile to recur, causing sepsis and interrupting cancer treatment.
A common diagnostic trap is benign biliary stricture: Surgery, pancreatitis, ischaemia and inflammatory disease can narrow ducts; persistent or progressive stricture requires repeated specialist sampling.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Chronic biliary inflammation

Primary sclerosing cholangitis, choledochal cysts, hepatolithiasis and liver-fluke infection increase cholangiocarcinoma risk through repeated epithelial injury.

Gallstone-related gallbladder injury

Long-standing gallstones, porcelain gallbladder and large polyps are associated with chronic inflammation and selected gallbladder cancers.

Metabolic and liver disease

Cirrhosis, viral hepatitis, diabetes and obesity contribute particularly to intrahepatic cholangiocarcinoma, although most cases remain sporadic.

Genomic drivers

FGFR2 fusions and IDH1 mutations occur mainly in intrahepatic disease, while HER2 amplification and other alterations vary by anatomical subtype.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Ductal obstruction
Perihilar and distal tumours narrow bile ducts, producing upstream cholestasis, pruritus, infection and impaired hepatic function.
2
Infiltrative growth
Biliary cancers spread longitudinally along ducts, through perineural planes and into portal structures, making margin assessment and resectability complex.
3
Segmental drainage
Hilar obstruction isolates right and left ductal systems, so draining an infected or future-liver-remnant segment requires planned imaging-based access.
4
Gallbladder invasion
A thin gallbladder wall permits early extension into liver and regional nodes; incidental depth determines whether completion resection is needed.
5
Molecular heterogeneity
Anatomical subtypes carry different actionable alterations, requiring adequate tissue and broad molecular testing in advanced disease.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Painless cholestatic jaundice

Extrahepatic obstruction causes jaundice, pruritus, dark urine and pale stool, often before a mass is palpable.

CholangitisRed flag

Fever, rigors, pain, confusion or shock with obstruction requires emergency antibiotics and drainage.

Intrahepatic mass pattern

Pain, weight loss or an incidental liver mass may occur without jaundice until disease is advanced.

PSC change

A new dominant or relevant stricture, worsening bilirubin, weight loss or rising CA 19-9 in PSC needs specialist investigation.

Incidental gallbladder carcinoma

Unexpected malignancy after cholecystectomy requires expert pathology review of depth, margin, perforation and specimen handling before further surgery.

Advanced disease

Ascites, hepatomegaly, nodal disease and declining performance indicate systemic spread or major vascular and biliary involvement.

Red flags requiring action

Progressive jaundice, dark urine, pale stool and pruritus suggests extrahepatic biliary obstruction.
Fever, rigors, right-upper-quadrant pain, hypotension or confusion with jaundice indicates cholangitis.
A patient with primary sclerosing cholangitis develops worsening cholestasis, weight loss or a dominant stricture.
A gallbladder mass, suspicious polyp or unexpected carcinoma is reported after cholecystectomy.
Unexplained right-upper-quadrant pain, weight loss or liver mass persists without jaundice.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Contrast CT chest, abdomen and pelvisFirst step
Why
Define primary anatomy, vascular involvement, nodes, metastases and broad resectability.
Interpretation and limitations
Use before unplanned drainage or biopsy where stable; perihilar disease needs expert review of future liver remnant and ductal anatomy.
02
MRI with MRCP
Why
Map longitudinal duct involvement, intrahepatic lesions and biliary anatomy for surgery or drainage.
Interpretation and limitations
This is especially valuable for perihilar tumours and avoids losing key anatomical information after stent artefact or decompression.
03
Endoscopic or percutaneous tissue
Why
Confirm unresectable or advanced disease and obtain molecular material using an anatomy-safe route.
Interpretation and limitations
Brushings alone have limited sensitivity; combine cytology, biopsy and molecular methods as appropriate, and avoid transperitoneal hilar-mass biopsy if transplant could be considered.
04
Image-guided core biopsy
Why
Confirm an intrahepatic mass, metastatic site or gallbladder lesion when histology will determine non-surgical therapy.
Interpretation and limitations
Plan the track with hepatobiliary specialists; distinguish adenocarcinoma metastasis, HCC and combined tumours through morphology and immunohistochemistry.
05
Liver tests, cultures and coagulation
Why
Assess obstruction, infection, synthetic dysfunction and procedural risk.
Interpretation and limitations
Take blood cultures before antibiotics when this does not delay therapy; correct vitamin-K deficiency and interpret bilirubin after drainage.
06
CA 19-9 and CEA
Why
Provide adjunctive baseline and response information in selected patients.
Interpretation and limitations
Neither marker diagnoses cancer; cholangitis, obstruction and Lewis-antigen status create misleading results.
07
Molecular profiling
Why
Identify FGFR2, IDH1, HER2, BRAF, NTRK and mismatch-repair targets in advanced biliary cancer.
Interpretation and limitations
Use adequate tissue and validated assays; anatomical subtype predicts but does not replace testing.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Benign biliary stricture

Surgery, pancreatitis, ischaemia and inflammatory disease can narrow ducts; persistent or progressive stricture requires repeated specialist sampling.

IgG4-related cholangitis

Autoimmune pancreatic and biliary inflammation can mimic hilar cancer, but empirical steroid before excluding malignancy can be hazardous.

Pancreatic or ampullary cancer

Distal obstruction may arise outside the bile duct and is separated by pancreatic-protocol imaging, endoscopy and tissue.

Hepatocellular carcinoma

An intrahepatic mass in chronic liver disease requires multiphase imaging and sometimes biopsy because treatment differs fundamentally.

Gallbladder inflammation

Xanthogranulomatous cholecystitis and complicated gallstone disease can appear infiltrative and need expert radiology and pathology. In Cholangiocarcinoma and gallbladder cancer, this distinction materially changes diagnostic assessment.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01MapDefine anatomy before interventionFirst stepBiliary or gallbladder cancer is suspected and the patient is stable without uncontrolled cholangitis.

1Obtain contrast CT and MRI/MRCP before stenting when feasible, then review ducts, vessels, lobar atrophy, future remnant and metastases in the hepatobiliary MDT.
2DefinitiveAvoid a casual transperitoneal biopsy of a potentially transplant-eligible hilar lesion; select tissue route with the definitive pathway in mind.
3Assess liver reserve, performance, nutrition, infection, coagulation and operative fitness alongside anatomical stage.

02DrainControl infected or clinically important obstructionCholangitis, severe pruritus, renal dysfunction or a treatment plan requires biliary decompression.

1Give sepsis treatment and arrange urgent ERCP for distal disease or anatomy-selected percutaneous or combined drainage for complex hilar obstruction.
2Drain the infected and intended functional liver segments rather than maximising the number of stents without a map.
3Record stent type, location and expected exchange or failure plan and recheck bilirubin before systemic-treatment dosing.

03ResectPursue curative surgery in a specialist centreDisease is localised, technically resectable and the person has adequate future liver and physiological reserve.

1For intrahepatic disease, perform oncological liver resection with regional nodal staging; for perihilar disease, resection often includes bile duct and liver.
2For incidental gallbladder cancer, review original pathology and consider completion liver-bed and nodal surgery according to T stage, margin and dissemination risk.
3Use adjuvant capecitabine when indicated after recovery, with pathology, margin, nodes and molecular findings documented.

04AdvancedUse systemic and biomarker-directed therapyBiliary cancer is unresectable, metastatic, recurrent or unsuitable for curative local treatment.

1Obtain sufficient histology before therapy and perform broad molecular profiling early enough to inform later lines.
2First lineUse gemcitabine–cisplatin with durvalumab for eligible first-line patients, modifying for renal, hearing, marrow, liver and performance limitations.
3At progression, consider an evidence-based chemotherapy or matched targeted treatment under current NHS access while maintaining drainage, nutrition, pruritus and palliative care.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Treats eligible advanced biliary-tract cancer after histological confirmation and multidisciplinary selection.

Durvalumab with gemcitabine and cisplatin

A licensed first-line schedule uses durvalumab 1,500 mg IV day 1 plus gemcitabine 1,000 mg/m² and cisplatin 25 mg/m² IV on days 1 and 8 every 21 days for up to 8 cycles, then durvalumab 1,500 mg every 4 weeks.

Monitor counts, renal and liver function, magnesium, hearing, neuropathy, infection and hydration, plus immune pneumonitis, colitis, hepatitis and endocrinopathy; cisplatin fitness and biliary sepsis require review before each dose.

Reduces recurrence risk after curative-intent resection in suitable biliary-tract cancer patients.

Capecitabine after resection

On each 21-day adjuvant cycle, give capecitabine 1,250 mg/m² orally morning and evening on days 1 through 14, for 8 cycles with protocol-led adjustment and lower starting doses where clinically indicated.

Confirm DPD status before fluoropyrimidine, review renal function, diarrhoea, mucositis, hand–foot syndrome and interactions, and stop urgently for severe early toxicity.

Binds bile acids and may reduce pruritus while definitive drainage or cancer treatment is arranged.

Colestyramine for cholestatic pruritus

Start 4 g orally once or twice daily and titrate, commonly up to four doses daily, separating it from other medicines by at least 4–6 hours according to their product information.

Can worsen constipation, bloating and fat-soluble-vitamin deficiency and binds many medicines; it will not treat cholangitis or a completely obstructed undrained system.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Recurrent cholangitis

Incomplete or occluded drainage allows infected bile to recur, causing sepsis and interrupting cancer treatment. In Cholangiocarcinoma and gallbladder cancer, this distinction materially changes complication assessment.

Liver failure

Extensive obstruction, small future liver remnant, vascular invasion or treatment injury can cause progressive jaundice and synthetic failure.

Stent occlusion

Sludge, tumour ingrowth or migration causes recurrent jaundice and infection and requires a documented re-intervention route.

Portal or hepatic vascular invasion

Vascular encasement and lobar atrophy limit resection and can worsen portal hypertension and hepatic reserve. In Cholangiocarcinoma and gallbladder cancer, this distinction materially changes complication assessment.

Peritoneal and liver spread

Occult dissemination may make major resection non-beneficial, supporting staging laparoscopy in selected high-risk disease. In Cholangiocarcinoma and gallbladder cancer, this distinction materially changes complication assessment.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

After drainage, trend temperature, bilirubin, ALP, renal function and symptoms and respond urgently to recurrent rigors or jaundice.
Before each systemic dose, review stent patency, infection, counts, renal and liver function, hearing, neuropathy and performance.
Track pathology and molecular results to completion before the treatment line at which they become actionable.
After resection, review margin, nodes, liver reserve, bile leak, cholangitis and readiness for adjuvant capecitabine.
Use protocolled imaging and symptom review to assess disease, distinguishing stent-related cholestasis from radiological progression.
Monitor nutrition, fat-soluble vitamins when relevant, pruritus, pain and advance-care priorities throughout treatment.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Anatomy comes before stent

MRCP performed before drainage often gives the clearest map for a complex hilar tumour and future liver remnant.

Drain with a purpose

In perihilar disease, a technically successful stent into the wrong atrophic segment may not improve bilirubin and can seed infection.

Protect transplant options

Transperitoneal biopsy of a hilar mass can compromise selected transplant pathways, so tissue route needs specialist agreement.

Markers follow obstruction

CA 19-9 may fall dramatically after drainage; a high obstructed value is not equivalent to cancer burden.

Molecular testing is anatomical

FGFR2 and IDH1 alterations enrich in intrahepatic disease but must be demonstrated rather than inferred from location.

11Common pitfallsFrequent interpretation and management errors.

01
Stenting complex hilar disease before obtaining an adequate ductal map.
02
Treating fever and jaundice with antibiotics without drainage source control.
03
Using CA 19-9 as histological proof.
04
Biopsying a potentially transplant-eligible hilar lesion through an unsafe track.
05
Starting systemic therapy before controlling biliary sepsis.
06
Sending inadequate brush cytology without planning core or molecular material.